Featured News Image news | May 9 2024 Wu Tsai Neurosciences Institute Psychedelics Inside Out: How do LSD and psilocybin alter our perceptions? (Part ... This week on From Our Neurons to Yours, we talk with anesthesiologist Boris Heifets about how psychedelics work in the brain. How do tiny quantities of these chemicals alter our perception of reality? And what does that say about... reality? Image news | May 7 2024 Wu Tsai Neuro Exploring MRI's role in neuroscience research on model organisms Recognizing the potential for wider application in small-animal neuroscience research, the Neurosciences Preclinical Imaging Lab (NPIL) at Wu Tsai Neuro hosted its 3rd annual symposium and named the recipients of its Pilot Grants. Image news | May 2 2024 Wu Tsai Neurosciences Institute Psychedelics, placebo, and anesthetic dreams This week on From Our Neurons to Yours, we talk with anesthesiologist Boris Heifets about studies that could change our understanding of the renaissance in psychedelic medicine Image news | Apr 15 2024 Wu Tsai Neurosciences Institute Neuroscience sheds light on childhood gut disorders The recent discovery that intestinal neurons normally self-organize into a striped pattern around the time of birth could help explain wide-ranging GI disorders in children, say Wu Tsai Neuro Faculty Scholar Julia Kaltschmidt and her team News Filter & Sort Sort by ThemeNeuroHealth News TypeResearch news Featured News Sort by Newest to oldest Oldest to newest Image news | Jan 9 2023 Wu Tsai Neuro The rebirth of psychedelic medicine Researchers at the the Wu Tsai Neurosciences Institute are at the forefront of a seismic shift that’s putting a spotlight on once taboo psychedelic substances as a promising new frontier in psychiatric medicine. Image news | Aug 29 2018 Stanford Medicine - Scope Opioid system plays key role in ketamine’s antidepressant effects, Stanford stud... For about a dozen years now, the drug ketamine has been a buzz word in psychiatric research circles. Many considered it the most exciting thing to emerge in decades to successfully treat treatment-resistant depression as well as other severe forms of psyc news | May 22 2017 Stanford Medicine - Scope Stanford researcher explores use of ketamine to treat severe mental illness Stanford researcher Carolyn Rodriguez, MD, PhD, was the first to explore ketamine as a treatment for OCD.
Image news | May 9 2024 Wu Tsai Neurosciences Institute Psychedelics Inside Out: How do LSD and psilocybin alter our perceptions? (Part ... This week on From Our Neurons to Yours, we talk with anesthesiologist Boris Heifets about how psychedelics work in the brain. How do tiny quantities of these chemicals alter our perception of reality? And what does that say about... reality?
Image news | May 7 2024 Wu Tsai Neuro Exploring MRI's role in neuroscience research on model organisms Recognizing the potential for wider application in small-animal neuroscience research, the Neurosciences Preclinical Imaging Lab (NPIL) at Wu Tsai Neuro hosted its 3rd annual symposium and named the recipients of its Pilot Grants.
Image news | May 2 2024 Wu Tsai Neurosciences Institute Psychedelics, placebo, and anesthetic dreams This week on From Our Neurons to Yours, we talk with anesthesiologist Boris Heifets about studies that could change our understanding of the renaissance in psychedelic medicine
Image news | Apr 15 2024 Wu Tsai Neurosciences Institute Neuroscience sheds light on childhood gut disorders The recent discovery that intestinal neurons normally self-organize into a striped pattern around the time of birth could help explain wide-ranging GI disorders in children, say Wu Tsai Neuro Faculty Scholar Julia Kaltschmidt and her team
Image news | Jan 9 2023 Wu Tsai Neuro The rebirth of psychedelic medicine Researchers at the the Wu Tsai Neurosciences Institute are at the forefront of a seismic shift that’s putting a spotlight on once taboo psychedelic substances as a promising new frontier in psychiatric medicine.
Image news | Aug 29 2018 Stanford Medicine - Scope Opioid system plays key role in ketamine’s antidepressant effects, Stanford stud... For about a dozen years now, the drug ketamine has been a buzz word in psychiatric research circles. Many considered it the most exciting thing to emerge in decades to successfully treat treatment-resistant depression as well as other severe forms of psyc
news | May 22 2017 Stanford Medicine - Scope Stanford researcher explores use of ketamine to treat severe mental illness Stanford researcher Carolyn Rodriguez, MD, PhD, was the first to explore ketamine as a treatment for OCD.